AngioScore Inc. announced the completion of enrollment in the Drug-Coated AngioSculpt Scoring Balloon Catheter First-in-Human (FIH) Study (PATENT-C). AngioScore anticipates that preliminary data from this study will be available for presentation at the Transcatheter Cardiovascular Therapeutics (TCT) conference to be held this fall in San Francisco


Toshiba America Medical Systems Inc. has partnered with Unfors RaySafe Inc. to offer a new radiation dose monitoring and management tool for Infinix-i cardiovascular X-ray systems. The Unfors RaySafe i2 displays real-time dose exposure information, helping to make exams safer for all clinical staff.

July 22, 2013 — A new report issued by the American College of Cardiology (ACC) and developed in collaboration with 10 other professional societies provides detailed criteria to help clinicians optimize the appropriate use of certain noninvasive vascular tests when caring for patients with known or suspected disorders of the venous system.


T2 Biosystems announced the presentation of data strongly correlating T2Hemostat results with patients’ clinical outcomes. In 26 patients who presented with chest pain and underwent cardiac catheterization, T2HemoStat was compared to a common platelet activity assay, where T2HemoStat accurately correlated to 100 percent of bleeding event cases while the comparator did not identify bleeding events in any patients. T2HemoStat also correlated to twice the number of thrombotic cases than the comparator. These data are complemented by additional presentations that demonstrate T2MR’s ability to identify novel clot biology, which may account for previously unexplained clot behavior while providing new clinical insights into the formation and degradation of blood clots. T2HemoStat is the company’s novel system for the rapid detection of physical changes in a blood sample, identifying novel clot biology while also measuring hemostasis characteristics such as coagulation, fibrinolysis and platelet function from finger stick size, small volumes of whole blood or plasma on a single, compact instrument.

 

July 19, 2013 — The Mount Sinai Medical Center is the first medical center in New York City to offer the HeartMate II pocket controller, newly approved by the U.S. Food and Drug Administration (FDA). This latest-generation controller for the HeartMate II left ventricular assist device (LVAD) is a new small, lightweight, patient-friendly external controller about the size of a smart phone.


Itamar-Medical announced that the American Medical Association (AMA) has awarded a Current Procedure Terminology (CPT) Category III reimbursement code to a test performed by its EndoPAT proprietary device.

Abbott announced that it has entered into an agreement to purchase IDEV Technologies, a privately held company focused on developing next-generation medical devices for use by interventional radiologists, vascular surgeons and cardiologists. Under the terms of the agreement, Abbott will acquire all outstanding equity of IDEV Technologies for $310 million net of cash and debt.

Subscribe Now